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Rationale: Thepredictivevalueof longitudinal change inBODE(Body
mass index, airflow Obstruction, Dyspnea, and Exercise capacity)
indexhas received limitedattention.Wehypothesized thatdecrease
in a modified BODE (mBODE) would predict survival in National
Emphysema Treatment Trial (NETT) patients.
Objectives: To determine how the mBODE score changes in patients
with lung volume reduction surgery versusmedical therapy and cor-
relations with survival.
Methods: Clinicaldatawere recordedusingstandardized instruments.
The mBODE was calculated and patient-specific mBODE trajectories
during 6, 12, and 24 months of follow-up were estimated using
separate regressions for each patient. Patients were classified as
having decreasing, stable, increasing, or missing mBODE based on
their absolute change frombaseline. The predictive ability ofmBODE
change on survival was assessed using multivariate Cox regression
models. The index of concordance was used to directly compare the
predictive ability of mBODE and its separate components.
Measurements and Main Results: The entire cohort (610 treated med-
ically and 608 treated surgically) was characterized by severe airflow
obstruction,moderate breathlessness, and increasedmBODE at base-
line.AwidedistributionofchangeinmBODEwasseenat follow-up.An
increase inmBODEofmore than1pointwasassociatedwith increased
mortality in surgically and medically treated patients. Surgically
treated patients were less likely to experience death or an increase
greater than1 inmBODE. Indicesofconcordance showedthatmBODE
change predicted survival better than its separate components.
Conclusions: ThemBODE demonstrates short- and intermediate-term
responsiveness to intervention in severe chronic obstructive pulmo-
narydisease. Increase inmBODEofmorethan1point frombaseline to
6, 12, and 24 months of follow-up was predictive of subsequent
mortality. Change inmBODEmayprove a good surrogatemeasure of
survival in therapeutic trials in severe chronic obstructive pulmonary
disease.
Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).
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Modifying disease in chronic obstructive pulmonary disease
(COPD) has become an increasingly feasible therapeutic option
in patients with COPD. Decreasing mortality is particularly
important in this disorder, which has exhibited a rising mortality
over the past several decades (1). Clinical treatments that seek to
improve mortality in COPD require large populations studied for
long periods. A recently completed pharmacologic intervention
resulted in a modest trend to improved survival despite more than
6,000 patients randomized to four treatment arms (2). It is very
desirable to have a ‘‘marker’’ that can be used as a surrogate for
survival to circumvent the need for large or prolonged trials. One
such measure, the multidimensional BODE (Body mass index,
airflow Obstruction, Dyspnea, and Exercise capacity) index, has
recently been shown to predict survival in cohort studies of
COPD (3, 4). However, for a surrogate outcome to be valid,
two other conditions should be satisfied. First, the measure should
be responsive to treatments that improve survival. Second, the
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The BODE index has prognostic value with respect to chronic
obstructive pulmonary disease mortality, although the im-
portance of change in BODE has received limited attention.
What This Study Adds to the Field
In a cohort of patients with severe emphysema, an increase
in modified BODE of more than 1 is associated with
increased mortality. Change in modified BODE also
predicted survival better than its separate components.
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measure should show a dose–response relationship—that is, those
patients who show the greatest improvement have the greatest
increase in survival and those who show the least improvement (or
greatest worsening) should have the greatest decrease in survival.
The BODE index has partially satisfied the first of these conditions
in an uncontrolled study of rehabilitation (5) and in three un-
controlled studies of lung volume reduction surgery (LVRS) (6–
8). Moreover, those patients who demonstrated greater decreases
in BODE index tended to have the best survival. Because these
studies were uncontrolled, however, it is possible that these results
could have reflected, in part, the natural variation in disease over
time rather than the effect of therapeutic interventions alone.
The National Emphysema Treatment Trial (NETT) provides
an ideal dataset to examine the relationship of changes in BODE
index to survival insofar as it compares an active intervention
(LVRS) with maximal medical therapy in a randomized trial of
patients with severe COPD. The modified BODE (mBODE) has
previously been shown to be a good predictor of survival in the
NETT population (4). We hypothesized that the NETT popula-
tion would allow a clear definition of the natural history of
BODE, and that the wide distribution of longitudinal changes
in BODE would allow a more clearly defined assessment of the
magnitude of change that reliably predicts subsequent mortality.
In the present analysis, the predefined specific goals were to
answer the following questions:
d Does the mBODE score improve with LVRS more than
maximal medical therapy?
d Does an improvement or worsening of mBODE correlate
with improved or worsening survival within each treatment
group?
d Does the magnitude of change in BODE predict the
magnitude of improvement in survival?
METHODS
Patient Selection
The study group consisted of all patients randomized to medical or
surgical therapy at 17 NETT clinics (9). The design and methods of the
trial have been previously detailed (9, 10). All patients provided written,
informed consent, and the institutional review board at each clinic
approved the study. Baseline measurements were completed after
pulmonary rehabilitation and before randomization. All patients com-
pleted 16 sessions of pulmonary rehabilitation before randomization and
6 sessions of rehabilitation postrandomization. Some patients in both
treatment arms of the study received further maintenance pulmonary
rehabilitation either through outpatient or home-based pulmonary
rehabilitation programs. Maximal medical therapy for patients also
included medical therapies such as bronchodilators, inhaled cortico-
steroids, and close monitoring of abstinence from tobacco use.
Clinical Assessment
Demographic data and smoking and medical history were collected by
patient interview using standardized instruments. Dyspnea was quan-
tified using the University of California San Diego Shortness of Breath
Questionnaire (UCSD SOBQ) (11).
Physiologic Testing
Patients underwent spirometry and plethysmographic lung volume
measurement after the administration of albuterol; diffusing capacity,
respiratory pressures, and arterial blood gases were also measured. The
protocol used for six-minute-walk testing (6MWT) has been described
in detail and provided the maximal distance walked (12).
Modified BODE
The BODE index is an 11-point composite score (0 through 10) in
which higher scores indicate poorer outcomes (3). We modified the
original BODE by using the UCSD SOBQ as the dyspnea measure
because the Medical Research Council dyspnea scale was not used in
NETT; this modified BODE demonstrated similar predictive ability in
patients with severe emphysema (4).
Statistical Analysis
Means of mBODE over time were estimated and tested using the
mixed models framework, which adjusts for bias due to patients being
lost to attrition over time. Patient-specific mBODE trajectories were
estimated using individual linear regressions applied to data available
from randomization to 6, 12, or 24 months. For patients surviving
beyond each of these times the estimated absolute change in mBODE
from baseline was obtained. Vital status was assessed by review of
records at each institution and supplemented by the use of the Social
Security Death Master File ensuring complete capture of data.
On the basis of the absolute change in mBODE at 6, 12, and 24
months elapsed since randomization and available data, patients were
classified into four distinct groups at each time point: (1) mBODE
decreased by greater than 1 point, (2) mBODE remains stable, (3)
mBODE increased greater than 1 point, (4) data missing for mBODE
calculation. Survival was estimated both within each treatment arm and
in the overall cohort, on the basis of multivariate Cox regression models,
while adjusting for sex, ethnicity, baseline age, and baseline mBODE. To
assess the Cox model fit and to directly compare mBODE mortality
predictive power with that of each of its components, the index of
concordance was computed. This measures model fit by calculating the
percentage of times observed mortality pairs are correctly ordered by the
model. Higher values are reflective of increasingly better model fit.
RESULTS
The entire cohort was characterized by elderly patients with
severe airflow obstruction, moderate breathlessness, and in-
creased mBODE (Table 1). At baseline, there were no differ-
ences in mBODE between the medical and surgical arms. Tables
2 and 3 give insight into the magnitude of mBODE differences
between the two treatment arms over time and formally compare
the two arms based on mixed model results that adjust for
attrition of repeated measures. As shown in Table 3, surviving
surgically treated (LVRS) patients presented negative slopes at 6,
12, and 24 months postrandomization on average, whereas
medically treated patients had significantly higher (P value
always less than 0.001) positive mBODE slopes at each time
mark postrandomization. As such, LVRS patients showed a con-
sistent pattern of mBODE decrease (improvement), whereas
medically treated patients exhibited significant increases (de-
terioration) in mBODE. The distribution of change in mBODE
among survivors at 6 (Figure 1), 12 (Figure E1A of the online
supplement), and 24 months (Figure E1B) is illustrated by plot. It
is evident that the entire cohort exhibits a wide range of scores at
each landmark time, with negative changes in mBODE (improve-
ments) more frequent in surgically treated patients. Significant
missing data were seen, particularly in medically treated patients.
Among those who survived to 6, 12, and 24 months after
randomization (Table E1), subtle differences were observed in
component variables of the mBODE at baseline in both the
medical and surgical groups, making formal treatment compar-
isons among survivors over time inappropriate. When patients
were grouped by survival duration, there was a clear gradient in
baseline FEV1 and baseline dyspnea, with those who survived
24 months having higher FEV1 and lower dyspnea at baseline
than those who did not survive as long.
The influence of changes in mBODE on subsequent mortality
was assessed by computing individual trajectories on the basis of
each patient’s available mBODE patient history available at 6
(Figure 2), 12 (Figure E2), and 24 months (Figure E2) postran-
domization. The mortality characteristics of the entire cohort
(Figure 2A), surgically treated patients (Figure 2B), and medi-
cally treated patients (Figure 2C) 6 months after randomization
are illustrated in Figure 2 by prior change in mBODE. Similar
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curves for 12 and 24 months after randomization are illustrated in
Figure E2. It is evident that there are distinct groups with
significantly different survival experiences in the entire cohort,
in surgically treated patients, and in medically treated patients.
Figure 3 illustrates how a decrease in mBODE of greater than 1
point at 6 months postrandomization in the entire cohort was
associated with a significant decrease in subsequent mortality
(hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.41–0.78;
P, 0.001), whereas an increase in mBODE of more than 1 point
was associated with a significantly increased mortality (HR, 2.35;
95% CI, 1.71–3.23; P , 0.001). Patients with missing data at
6 months experienced an intermediate increase in mortality (HR,
1.45; 95% CI, 1.10–1.92; P 5 0.01). Similar results were noted in
the entire cohort at 12 and 24 months postrandomization. In the
surgically treated cohort, a decrease in mBODE of more than 1
point at 6 months was suggestive of improved subsequent survival
(HR, 0.72; 95% CI, 0.48–1.08; P5 0.110), with a similar trend at
12 and 24 months postrandomization becoming statistically
significant. Hazards associated with an increase in mBODE of
greater than 1 point or missing data were somewhat higher in the
surgical arm compared with the medical arm; otherwise, hazards
in both treatment arms were ordered very similarly to the overall
cohort and were highly statistically significant. An exploratory
analysis confirmed that a change of 1 point in mBODE better
distributed survival curves than other thresholds, including a
2-point change in mBODE (data not shown).
Figure 4 illustrates event-free rates associated with the
composite outcome of death or an increase in mBODE of more
than 1 point. The median time to this composite event was
significantly shorter in medically treated patients (3.65 yr; 95%
CI, 3.21–4.37 yr) compared with LVRS-treated patients (5.68 yr;
95% CI, 4.93 yr–not available). Table 4 demonstrates indices of
concordance for mBODE, 6MWT, and UCSD SOBQ. The
index of concordance allows us to quantify the predictive ability
of a survival model. As can be seen from the table, mBODE
exhibits indices of concordance consistently higher than those
obtained for FEV1, 6MWT distance, and the UCSD SOBQ
alone, indicating that the predictive ability of the mBODE for
survival is better than any of the individual components. On the
other hand, it appears that change in UCSD SOBQ likely
accounted for much of the mBODE’s predictive ability.
DISCUSSION
Reducing mortality has become increasingly feasible in COPD.
Therapeutic trials designed to demonstrate improved survival
require large study design with prolonged periods of follow-up.
As such, identifying reliable surrogates of survival in COPD has
become an important concept. Multidimensional indices, such
as the BODE index, evaluated at baseline have been shown to
exhibit greater predictive values than the individual compo-
nents of the index. Recently, three uncontrolled studies have
suggested that the BODE index changes after therapeutic
intervention and that this change appears to relate to sub-
sequent mortality (5, 6). These studies have been limited by lack
of control groups. The current analysis describes longitudinal
TABLE 1. PATIENT BASELINE CHARACTERISTICS
Entire Cohort (n) Medical (n) LVRS (n) P Value
Sex 0.041*
Male 746 391 355
Female 472 219 253
Total 1,218 610 608
Ethnicity 0.751
White 1,156 575 581
African American 42 23 19
Hispanic 5 3 2
Other 15 9 6
Total 1,218 610 608
n Mean (SD) n Mean (SD) n Mean (SD)
Age, yr 1,218 67.14 (6.12) 610 67.22 (5.90) 608 67.05 (6.34) 0.619
FEV1% predicted 1,218 26.75 (7.20) 610 26.68 (7.03) 608 26.83 (7.37) 0.725
6MWT distance, ft 1,218 1,217.70 (314.17) 610 1218.9 (315.99) 608 1216.5 (312.58) 0.891
UCSD SOBQ 1,218 62.48 (18.33) 610 63.39 (18.55) 608 61.56 (18.07) 0.082
BMI 1,217 24.6 (3.6) 609 24.7 (3.5) 608 24.5 (3.7) 0.294
mBODE 1,217 5.02 (1.67) 609 5.05 (1.68) 608 5.00 (1.66) 0.607
Definition of abbreviations: BMI 5 body mass index; LVRS 5 lung volume reduction surgery; mBODE 5 modified BODE (Body
mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index; 6MWT 5 six-minute-walk test; UCSD SOBQ 5 University
of California San Diego Shortness of Breath Questionnaire.
*x2 test comparing sex differences in medical and LVRS treatment arms: P value , 0.05.
TABLE 2. MEAN (SD) mBODE INDEX IN MEDICALLY TREATED AND LUNG VOLUME REDUCTION
SURGERY PATIENT GROUPS AT 6, 12, AND 24 MONTHS POSTRANDOMIZATION
Time Since
Randomization
Entire Cohort Medical Arm LVRS Arm
T Value df P Valuen Mean (SD) n Mean (SD) n Mean (SD)
6 Months 881 4.60 (1.44) 412 5.07 (1.41) 469 4.18 (1.33) 9.58 850 ,0.001
12 Months 711 4.43 (1.51) 327 5.13 (1.44) 384 3.84 (1.30) 12.46 664 ,0.001
24 Months 587 4.12 (1.65) 260 5.23 (1.35) 327 3.24 (1.29) 18.15 543 ,0.001
Definition of abbreviations: df 5 degrees of freedom; LVRS 5 lung volume reduction surgery; mBODE 5 modified BODE (Body
mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index.
Results are based on mixed model adjusting for patient sex, ethnicity, baseline age, and baseline mBODE.
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changes in a highly characterized, large cohort of patients with
severe emphysema, half of whom underwent a therapeutic
intervention that resulted in significant improvement. As such,
we report the following: (1) the mBODE is responsive to
longitudinal changes with greater improvement in surgically
compared with medically treated patients; (2) a decrease in
mBODE of more than 1 point was predictive of lesser mortality
in the entire cohort and, particularly, the surgically treated
cohort; (3) an increase of mBODE of more than 1 point was
predictive of greater mortality, a finding more consistently seen
in the medically treated patients; (4) analysis of concordance
suggests that the mBODE is more predictive of survival than
the changes in its individual components; and (5) short-term
changes in a composite endpoint (mBODE increase of.1 point
or death) may serve as a valuable surrogate of mortality in
future COPD studies.
We confirm that the mBODE changes over 6 to 24 months in
patients with severe COPD. Interestingly, the entire cohort
illustrated similar numbers of patients who exhibited increases
or decreases in mBODE. Importantly, medically treated patients
appeared to experience a lesser change in mBODE, with most of
the change seen in increasing values, suggesting a worsening score
in this multidimensional index. A separate report noted similar,
subtle change in BODE in a cohort of patients, some of whom
were treated with pulmonary rehabilitation (5). Although the
influence of additional pulmonary rehabilitation in the current
cohort cannot be directly assessed, our work expands previous
data by providing insight into the natural history of longitudinal
change in mBODE in a large cohort of patients with severe
emphysema treated with maximal medical therapy. Furthermore,
these data allow the calculation of the expected natural history of
the mBODE in such patients over a 2-year time frame. These data
can be used to define expected changes in mBODE in future
therapeutic trials that wish to use this composite index as
a treatment outcome.
Our data provide a contrast in that surgically treated patients
exhibit a wider distribution of changes in scores, with a larger
number of patients experiencing decreasing, or improving,
scores. These data expand on the original observations of the
NETT that confirmed functional improvements in surgically
compared with medically treated patients with severe emphy-
sema (9). Two groups have recently presented results of short-
term (3 mo) and intermediate-term (12–24 mo) changes in BODE
in a small group of patients with emphysema treated with LVRS
that document a similar distribution of change, with the majority
of patients exhibiting decreases in scores (6–8). Our data extend
these observations by illustrating the natural history of change in
mBODE over a 2-year period, and are strengthened by having
a similar medically treated patient group for comparison. Direct
survival comparison of surgically versus medically treated
patients by mBODE change is limited by differential mortality
over the period of measurements. Nevertheless, the totality of
these data provides insight into the potential change in mBODE
in patients with severe COPD treated with a therapy that provides
marked functional improvements.
Our data provide important insight into how short- and
intermediate-term changes in a composite index can be used to
predict mortality in a large group of medically and surgically
treated patients with severe COPD. In both medically and
surgically treated patients, an increase in mBODE was associated
with an increased risk of mortality in subsequent follow-up. This
was noted as early as 6 months and out to 2 years after
randomization to intervention. Furthermore, a greater than 1
point increase in mBODE was associated with a 1.9- to 2.1-fold
increase in mortality in medically treated patients and a 2.5- to
3.6-fold increase in surgically treated patients. We also noted that
a decrease in mBODE of greater than 1 point after 12 months was
associated with improved subsequent mortality only in surgically
treated patients. These data expand on results from other groups
that suggest that a decrease in BODE is associated with decreased
subsequent mortality in surgically treated patients (6) by illus-
trating that changes in mBODE are predictive of subsequent
mortality from as short as 6 months of follow-up to 24 months of
follow-up. An important finding of our study is the ability to
TABLE 3. MEAN mBODE SLOPES IN UNITS/TIME PERIOD (SD) IN MEDICALLY TREATED AND LUNG
VOLUME REDUCTION SURGERY PATIENT GROUPS AT 6, 12, AND 24 MONTHS POSTRANDOMIZATION
Time Since
Randomization
Entire Cohort Medical Arm LVRS Arm
T Value df P Valuen Mean (SD) n Mean (SD) n Mean (SD)
6 Months 881 20.11 (0.35) 412 0.14 (0.21) 469 20.33 (0.32) 26.07 813 ,0.001
12 Months 711 20.30 (0.86) 327 0.41 (0.44) 384 20.90 (0.66) 31.48 674 ,0.001
24 Months 587 20.23 (0.62) 260 0.38 (0.22) 327 20.72 (0.33) 47.80 568 ,0.001
For definition of abbreviations, see Table 2.
Results are based on mixed model adjusting for patient sex, ethnicity, baseline mBODE, and baseline age.
Figure 1. The percentage of patients
(x axis) experiencing changes in mBODE
(modified Body mass index, airflow Ob-
struction, Dyspnea, and Exercise capac-
ity) (y axis) 6 months after randomization
to medical therapy or bilateral lung vol-
ume reduction surgery (LVRS). Patients
who had died or were not able to pro-
vide data to calculate mBODE at each
time point are also illustrated.
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describe the time to death or to an increase in mBODE in
medically and surgically treated patients. These data can be used
to construct clinical trials of therapeutic interventions that may
improve mortality with a smaller sample size over a period as
short as 6 months.
We also provide insight into the operating characteristics of
a composite index in contrast to some of the individual compo-
nents. An analysis of concordance demonstrates that the com-
posite index was better able to predict subsequent mortality in the
entire cohort as well as in the medically and surgically treated
patients. A higher index of concordance was evident for the
composite mBODE index at 6, 12, and 24 months after in-
tervention. Further examination suggests that the majority of
change in mBODE was contributed by improved dyspnea. Our
Figure 2. Kaplan-Meier survival curves (starting at 6 months after randomization [F06]) for the entire cohort (A), surgically treated patients (lung
volume reduction surgery [LVRS] arm) (B), and medically treated patients (C) in patients who survived and were able to provide data to calculate
mBODE (modified Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) 6 (F06) months after randomization. Survival curves are
segregated by groups who experienced a decrease in mBODE . 1 (blue), a rise in mBODE . 1 (red), no change in mBODE (21 to 1 point change)
(green), or missing data (black) from baseline to the starting time point. (A) Log rank5 46.9; degrees of freedom5 3; P value, 0.01. (B) Log rank5 53;
degrees of freedom 5 3; P value , 0.01. (C) Log rank 5 7.58; degrees of freedom 5 3; P value < 0.06.
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data extend the findings of others that have suggested that change
in 6MWD over 1 year predicts survival (13) by contrasting change
in exercise capacity with longitudinal changes in dyspnea, FEV1,
and a composite index incorporating all of these factors.
Limitations of this study come from its highly selective sample
population. All subjects were enrolled in NETT, a randomized
trial of LVRS for patients with a predominantly emphysematous
phenotype. As such, selection bias was imposed by requirements
for a highly selected subset of patients with severe COPD. In
addition, the mBODE was a modification of the original multi-
dimensional index. On the other hand, the operating character-
istic of the mBODE was remarkably similar with regard to
prognostic ability (4) to the original index (3). In addition, the
predictive ability of a greater than 1-unit change in mBODE was
similar to that noted for changes in a broader spectrum of patients
with COPD undergoing rehabilitation in a smaller, uncontrolled
study (5). Finally, although no patients were lost to follow-up, we
are missing data whenever a patient was unwilling or unable to
complete any one component of the mBODE. This was partic-
ularly evident in medically treated patients. It is difficult to know
if this led to any systematic bias in our reported results because
the predictive ability of change in mBODE is conditional on the
ability of patients to contribute data at the respective time points.
Interestingly, we noted that those with missing data experienced
a higher mortality than those with no change in mBODE,
although those with rising mBODE generally appeared to exhibit
even higher mortality.
In summary, we demonstrate that a composite index
(mBODE) demonstrates short- and intermediate-term respon-
siveness to intervention in severe COPD. This was more evident
in surgically treated than in medically treated patients. Further-
more, changes in mBODE at 6, 12, and 24 months of follow-up
were predictive of subsequent mortality. An increase in mBODE
of greater than 1 point proved predictive of mortality. Impor-
Figure 2. (Continued).
Figure 3. Multivariate Cox survival models comparing the predictive value of change in mBODE (modified Body mass index, airflow Obstruction,
Dyspnea, and Exercise capacity) at 6, 12, and 24 months postrandomization, adjusted for sex, ethnicity, baseline age, and baseline mBODE. LVRS5
lung volume reduction surgery.
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tantly, the changes in the individual parameters were not as
predictive of subsequent survival as individual components.
These changes provide support that a short- and intermediate-
term change in a multidimensional composite index may be used
as a surrogate for survival in clinical trials.
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TABLE 4. CONCORDANCE INDICES FOR (CHANGE IN) mBODE
INDEX AND THREE OF ITS COMPONENTS (EXCEPT FOR
BODY MASS INDEX) BY STUDY ARM AND FOR THE ENTIRE




6 Months 12 Months 24 Months
Entire cohort
n 1,034 939 819
mBODE 0.66 0.68 0.69
FEV1 0.58 0.59 0.61
6MWD 0.61 0.63 0.64
UCSD SOBQ 0.64 0.65 0.65
Medical arm
n 515 476 393
mBODE 0.64 0.68 0.67
FEV1 0.57 0.62 0.61
6MWD 0.59 0.64 0.63
UCSD SOBQ 0.61 0.64 0.65
LVRS arm
n 519 463 426
mBODE 0.68 0.68 0.72
FEV1 0.61 0.61 0.66
6MWD 0.65 0.61 0.67
UCSD SOBQ 0.67 0.65 0.65
Definition of abbreviations: LVRS 5 lung volume reduction surgery; mBODE 5
modified BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise
capacity) index; 6MWT 5 six-minute-walk test; UCSD SOBQ 5 University of
California San Diego Shortness of Breath Questionnaire.
Indices are calculated based on Cox regression models adjusting for patient
sex, ethnicity, and baseline age.
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